NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron, Inc. (NASDAQ: REGN) on behalf of long-term stockholders. Our investigation concerns whether the board of directors of Regeneron have breached their fiduciary duties to the company.

On June 24, 2020, U.S. Department of Justice filed a lawsuit alleging that the Company has violated the False Claim Act and actively engaged in a kickback scheme to bolster its sale of macular degeneration drug, Eylea.

Beginning in 2012, the Company began to pay Chronic Disease Fund to cover Medicare co-pays for Eylea patients so the doctors would prescribe them, and the Company would make an estimated 400% profit.

The Company has also been accused of lying to the government about their contributions to Chronic Disease Fund during a 2013 audit.

If you are a long-term stockholder of Regeneron, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com